A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954
4. září 2026 aktualizováno: AstraZeneca
An Open-Label Study to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and Absolute Bioavailability of AZD4954 in Healthy Male Participants
This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth. The test medicine will be radiolabelled with a small amount of carbon-14 so it can be tracked in the body.
This two-part study will take place at one site in Nottingham, United Kingdom, and will enroll 8 healthy men in each part, aged 30-65 years.
Přehled studie
Postavení
Zatím nenabíráme
Podmínky
Detailní popis
This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth. The test medicine will be radiolabelled with a small amount of carbon-14 so it can be tracked in the body.
This study will take place at one site in Nottingham, United Kingdom.
It is planned to enroll 8 healthy male participants in each part, aged 30-65 years.
In part 1 volunteers will receive a single dose of radiolabelled test medicine as a liquid by mouth. They'll stay in the clinic for up to 24 nights, attend 1 outpatient visit, and take up to 8 weeks to finish the study.
In part 2 volunteers will receive a single dose of test medicine by mouth and, shortly afterwards, a very tiny dose of radiolabelled study medicine by injection into a vein. They'll stay in the clinic for up to 15 nights, attend 1 outpatient visit, and take up to 7 weeks to finish the study.
Blood and urine samples will be collected to do safety tests. Blood, urine and faecal samples will be collected to measure the amount of test medicine and its breakdown products.
Typ studie
Intervenční
Zápis (Odhadovaný)
16
Fáze
- Fáze 1
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní kontakt
- Jméno: AstraZeneca Clinical Study Information Center
- Telefonní číslo: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Ano
Popis
Inclusion Criteria:
- Healthy males aged 30 to 65 years inclusive
- BMI of 18.0 to 35.0 kg/m2 inclusive
- Regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)
Exclusion Criteria:
- Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients
- Presence or history of clinically significant allergy requiring treatment
- History of clinically significant cardiovascular, renal, hepatic, respiratory, dermatological or gastrointestinal disease, and neurological or psychiatric disorder
- History of cholecystectomy or gall stones
- History of GI surgery
- Acute diarrhoea or constipation in the 7 days before the predicted Day 1
- Participants who do not have suitable veins for multiple venepunctures/cannulation
- Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis
- Evidence of renal impairment at screening
- Participants who have received any IMP in a clinical research study within the 90 days prior to Day 1
- Participants who have previously been administered IMP in this study
- Radiation exposure exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years
- Participants who have been administered IMP in an ADME study in the last 12 months
- Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
- Use of any prescribed or non-prescribed medication including antacids, gastric pH modifying agents, analgesics, herbal remedies, vitamins and minerals within 2 weeks of dosing
- Current smokers or known or suspected history of alcohol or drug abuse
- Excessive intake of caffeine-containing drinks or food
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Part 1
Participants in Part 1 will receive a single dose of [14C]AZD4954 Oral Solution.
|
Participants in Part 1 will recieve a single dose of [14C]AZD4954 oral solution
|
|
Experimentální: Part 2
Participants in Part 2 will receive a single unlabelled oral dose of AZD4954 tablet and a radiolabelled IV microtracer dose of [14C]AZD4954.
|
Participants in Part 2 will receive a single dose of AZD4954 film-coated tablet by mouth
Participants in Part 2 will receive a single very tiny dose of radiolabelled [14C]AZD4954 Solution for Infusion as a slow injection into a vein
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Amount of AZD4954 excreted (Ae) (Part 1)
Časové okno: Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
|
Mass balance recovery, rates and routes of elimination of total radioactivity of [14C] AZD4954 in urine, faeces and all excreta
|
Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
|
|
Amount of AZD4954 excreted expressed as a fraction of dose excreted (Fe) (Part 1)
Časové okno: Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
|
Mass balance recovery, rates and routes of elimination of total radioactivity of [14C] AZD4954 in urine, faeces and all excreta
|
Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
|
|
Cumulative amount of AZD4954 excreted (CumAe) (Part 1)
Časové okno: Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
|
Mass balance recovery, rates and routes of elimination of total radioactivity of [14C] AZD4954 in urine, faeces and all excreta
|
Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
|
|
Cumulative amount of AZD4954 excreted expressed as a fraction of dose excreted (CumFe) (Part 1)
Časové okno: Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
|
Mass balance recovery, rates and routes of elimination of total radioactivity of [14C] AZD4954 in urine, faeces and all excreta
|
Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
|
|
Absolute bioavailability (F) based on AUC0-inf (Part 2)
Časové okno: Plasma, urine and faecal samples from pre-dose until up to 336 hours post-dose
|
Absolute bioavailability of AZD4954 oral and IV administration, adjusted for dose
|
Plasma, urine and faecal samples from pre-dose until up to 336 hours post-dose
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Maximum observed concentration (Cmax) for AZD4954 and total radioactivity (Parts 1 and 2)
Časové okno: Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
|
The PK of AZD4954 and [14C]AZD4954 in plasma and urine, and total radioactivity in plasma and whole blood
|
Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
|
|
Time of maximum observed concentration (Tmax) for AZD4954 and total radioactivity (Parts 1 and 2)
Časové okno: Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
|
The PK of AZD4954 and [14C]AZD4954 in plasma and urine, and total radioactivity in plasma and whole blood
|
Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
|
|
Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for AZD4954 and total radioactivity (Parts 1 and 2)
Časové okno: Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
|
The PK of AZD4954 and [14C]AZD4954 in plasma and urine, and total radioactivity in plasma and whole blood
|
Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
|
|
Terminal elimination half-life (T1/2) for AZD4954 and total radioactivity (Parts 1 and 2)
Časové okno: Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
|
The PK of AZD4954 and [14C]AZD4954 in plasma and urine, and total radioactivity in plasma and whole blood
|
Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
|
|
Area under the curve (AUC) of circulating total radioactivity accounting for 10% or more of the dose (Part 1)
Časové okno: Plasma, urine and faecal samples collected from pre-dose until up to 552 hours post-dose
|
Identification of the chemical structure of each metabolite
|
Plasma, urine and faecal samples collected from pre-dose until up to 552 hours post-dose
|
|
80% or more of the radioactivity recovered in excreta (Part 1)
Časové okno: Plasma, urine and faecal samples collected from pre-dose until up to 552 hours post-dose
|
Identification of the chemical structure of each metabolite
|
Plasma, urine and faecal samples collected from pre-dose until up to 552 hours post-dose
|
|
Disposition of total radioactivity in plasma and in blood (Part 1)
Časové okno: Plasma, and whole blood samples collected from pre-dose until up to 552 hours post-dose
|
Evaluation of whole blood:plasma concentration ratios for total radioactivity
|
Plasma, and whole blood samples collected from pre-dose until up to 552 hours post-dose
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Sharan Sidhu, MBChB, BAO, MRCS, MFPM, Quotient Sciences
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Odhadovaný)
19. října 2026
Primární dokončení (Odhadovaný)
17. prosince 2026
Dokončení studie (Odhadovaný)
17. prosince 2026
Termíny zápisu do studia
První předloženo
4. září 2026
První předloženo, které splnilo kritéria kontroly kvality
4. září 2026
První zveřejněno (Aktuální)
10. září 2026
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
10. září 2026
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
4. září 2026
Naposledy ověřeno
1. srpna 2026
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- D7300C00005
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
ANO
Popis plánu IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org.
All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Časový rámec sdílení IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Kritéria přístupu pro sdílení IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environmentVivli.org.
Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .